SCHEMBL5158091

SCHEMBL5158091

CCN(CC)C(=O)CC(=O)c1cocn1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ACACB O00763 2/20 0.38
ALDH1A1 P00352 3/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
HSD17B10 Q99714 2/20 0.33
MAPT P10636 2/20 0.33
PIK3CD O00329 1/20 0.33
KDM4E B2RXH2 1/20 0.33
MDM2 Q00987 1/20 0.33
KMT2A Q03164 1/20 0.33
LMNA P02545 1/20 0.33
NPC1 O15118 2/20 0.33
RAB9A P51151 2/20 0.33
CYP3A4 P08684 1/20 0.33
RECQL P46063 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
RORC P51449 1/20 0.32
NAMPT P43490 1/20 0.32
POLB P06746 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5163302 0.83 ACACB (0.37) ACACBALDH1A1HSD17B10PIK3CDKDM4E
SCHEMBL19438494 0.78 PIK3CD (0.37) ACACBMAPTPIK3CDLMNANAMPT
SCHEMBL5163521 0.77 MGAM (0.44) ACACBALDH1A1SMN1; SMN2HSD17B10MAPT
SCHEMBL2632662 0.77
SCHEMBL5158427 0.75 ACACB (0.36) ACACBSMN1; SMN2PIK3CDKDM4ENPC1
SCHEMBL5160047 0.75 PIK3CD (0.35) ACACBSMN1; SMN2PIK3CDLMNA
SCHEMBL5160077 0.75 ACACB (0.38) ACACBALDH1A1SMN1; SMN2HSD17B10MAPT
SCHEMBL5161505 0.71 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2MAPTKDM4ELMNA
SCHEMBL5160391 0.71 APOBEC3A (0.34) ALDH1A1SMN1; SMN2HSD17B10MAPTKDM4E
SCHEMBL5160509 0.70 P2RX7 (0.50) ALDH1A1MAPTKDM4ELMNANPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8293899-B2 Ketone transfer hydrogenation of stereoisomerically enriched 3-heteroaryl-3-oxocarboxylic esters by reducing 3-heteroaryl-3-hydroxycarboxylic esters in the presence of a ruthenium-containing catalyst, an amine and formic acid and/or formates LANXESS DEUTSCHLAND GMBH (DE) 2012-10-23 US disclosed
EP-1340746-B1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives SALTIGO GMBH (DE) 2007-02-28 EP disclosed
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives LANXESS DEUTSCHLAND GMBH (DE) 2003-12-04 US disclosed
EP-1340746-A1 Process for the reduction of 3-heteroaryl-3-oxo-propanoic acid derivatives BAYER AG (DE) 2003-09-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030225274-A1 Process for reducing 3-heteroaryl-3-oxopropionic acid derivatives GRHPR, HPD, HAAO ACACB 76/4885ALDH1A1 273/4885SMN1; SMN2 4683/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.